Figure 7

Figure 7

Treatment of zebrafish ectopic and orthotopic CM models with TLD1433 through WA. (A) Schedule of tumour injection and TLD1433 administration in zebrafish embryos. Fluorescent CRMM1 and CRMM2 cells were injected at 2 dpf into the Duct of Cuvier (ectopic model) and behind the eye (orthotopic model) and TLD1433 was administered with or without a light treatment following the schedule presented in A. Relative tumour burden estimated as fluorescence intensity and tumour area was calculated by Image J. (B) CRMM1 tumour burden in ectopic model (n ≈ 30). (C) CRMM1 tumour burden in orthotopic model (n ≈ 15). (D) CRMM2 tumour burden in ectopic model (n ≈ 30). (E) CRMM2 tumour burden in orthotopic model (n ≈ 15). Results are presented as means ± SD from three independent experiments. Representative images show CM tumour burden in the head and tail regions in the ectopic model and a localised tumour in the orthotopic model.